First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX) Financings

First Tracks Biotherapeutics, Inc.

Financings

RaiseDate
Private placement of shares of common stock
Closed: US$200M raised · US$32.75 a share · Leerink Partners +3
Dealers: Leerink Partners, Piper Sandler, UBS Investment Bank, Wells Fargo Securities
Buyers: Affinity Asset Advisors, LLC; First Light Asset Management; Sirenia Capital Management LP; TCGX; Trails Edge Capital Partners; Vestal Point Capital
Use of proceeds: General corporate purposes, including clinical development of ANB033, a CD122 antagonist
Nov 3, 2026

Read by 6ix AI from the company's releases